Patient-reported outcomes in patients with primary immunodeficiency diseases in Japan: baseline results from a prospective observational study

被引:4
作者
Kanegane, Hirokazu [1 ]
Ishimura, Masataka [2 ]
Kawai, Toshinao [3 ]
Okada, Satoshi [4 ]
Okamatsu, Nobuaki [5 ]
Go, Madoka [6 ]
Noto, Shinichi [7 ]
机构
[1] Tokyo Med & Dent Univ TMDU, Grad Sch Med & Dent Sci, Dept Child Hlth & Dev, Tokyo, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Fukuoka, Japan
[3] Natl Ctr Child Hlth & Dev, Div Immunol, Tokyo, Japan
[4] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pediat, Hiroshima, Japan
[5] Takeda Pharmaceut Co Ltd, Med Franchise Plasma Derived Therapies, Japan Med Off, Tokyo, Japan
[6] Takeda Pharmaceut Co Ltd, Rare Dis Evidence Generat & Outcomes Res, Japan Med Off, Tokyo, Japan
[7] Niigata Univ Hlth & Welf, Dept Rehabil, Niigata, Japan
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
36-Item Short Form Health Survey (SF-36); activities of daily living; immunoglobulin replacement therapy; Japan; patient reported outcome measures; primary immunodeficiency diseases; quality of life; Work Productivity and Activity Impairment (WPAI) Questionnaire; QUALITY-OF-LIFE; IMMUNOGLOBULIN THERAPY; HEALTH SURVEY; PRODUCTIVITY; BURDEN; SF-36;
D O I
10.3389/fimmu.2023.1244250
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Primary immunodeficiency diseases (PIDs) are rare inherited diseases resulting in impaired immunity. People with PID experience lower health-related quality of life (HR-QOL) and disease-related burdens in daily activities. This ongoing, prospective observational study aims to evaluate disease activity, treatment status, treatment-related burden, daily activities, and HR-QOL in patients with PID in Japan over a 1-year period. In this interim report (database lock: July 29, 2022), we present baseline results.Methods Participants were enrolled between November 2021 and May 2022; data were collected four times/year per participant until May 2023 using an online electronic patient-reported outcomes system. Patients with PID and healthy volunteers aged >= 12 years, residing in Japan, and with access to a smartphone were eligible. HR-QOL (primary endpoint) was assessed by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) and the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Work productivity was assessed by the Work Productivity and Activity Impairment (WPAI) Questionnaire. Other aspects of PID and burden were assessed with a new questionnaire developed in-house. The study is registered at the University hospital Medical Information Network clinical trials registry (UMIN000045622).Results The full interim analysis set comprised 71 patients with PID and 47 healthy volunteers. The most common International Union of Immunological Societies PID category was primary antibody deficiency (56.3% of patients). Complications were common, especially recurrent respiratory tract infections (63.4%). Most patients with PID were treated with immunoglobulin replacement therapy (73.2%); 22.4% of these patients had serum immunoglobulin levels <700 mg/dL. Among patients who did not undergo hematopoietic cell transplantation, EQ-5D-5L (n=67) and SF-36 (n=59) Physical and Mental Component Summary scores were significantly lower than in healthy volunteers (p < 0.001). WPAI absenteeism, work productivity loss, and activity impairment scores were significantly lower in 42 working patients with PID than in 37 working healthy volunteers (p < 0.05). Other results indicated that patients with PID experience substantial burdens related to medical visits, expenses, work, and daily activities.Discussion This interim analysis confirms that patients with PID in Japan have lower HR-QOL and work productivity compared with healthy individuals and experience substantial limitations and burdens in their daily lives.
引用
收藏
页数:13
相关论文
共 31 条
[1]   How effective are the 6 European Society of Immunodeficiency warning signs for primary immunodeficiency disease? [J].
Arslan, Sevket ;
Ucar, Ramazan ;
Caliskaner, Ahmet Zafer ;
Reisli, Ismail ;
Guner, Sukru Nail ;
Sayar, Esra Hazar ;
Baloglu, Ismail .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 116 (02) :151-+
[2]   Primary antibody deficiency: The impact on the quality of life and mental health of affected children and their parents [J].
Berg, Annika Klungland ;
Diseth, Trond H. ;
Abrahamsen, Tore Gunnar ;
Halvorsen, Kathleen ;
Reinfjell, Trude ;
Erichsen, Hans Christian .
ACTA PAEDIATRICA, 2021, 110 (05) :1645-1652
[3]   Key aspects for successful immunoglobulin therapy of primary immunodeficiencies [J].
Cunningham-Rundles, C. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2011, 164 :16-19
[4]  
EFPIA-Japan, 2018, Primary immunodeficiency (PID). Survey on the treatment and quality of life of patients. Results of the questionnaire survey
[5]   A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases [J].
Epland, Kristin ;
Suez, Daniel ;
Paris, Kenneth .
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2022, 18 (01)
[6]  
Espanol T, 2014, PATIENT PREFER ADHER, V8, P621, DOI [10.2147/PPA.S60771, 10.2147/PPA.S.60771]
[7]   Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan [J].
Fukuhara, S ;
Bito, S ;
Green, J ;
Hsiao, A ;
Kurokawa, K .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1037-1044
[8]   Clinical picture and treatment of 2212 patients with common variable immunodeficiency [J].
Gathmann, Benjamin ;
Mahlaoui, Nizar ;
Gerard, Laurence ;
Oksenhendler, Eric ;
Warnatz, Klaus ;
Schulze, Ilka ;
Kindle, Gerhard ;
Kuijpers, Taco W. ;
van Beem, Rachel T. ;
Guzman, David ;
Workman, Sarita ;
Soler-Palacin, Pere ;
De Gracia, Javier ;
Witte, Torsten ;
Schmidt, Reinhold E. ;
Litzman, Jiri ;
Hlavackova, Eva ;
Thon, Vojtech ;
Borte, Michael ;
Borte, Stephan ;
Kumararatne, Dinakantha ;
Feighery, Conleth ;
Longhurst, Hilary ;
Helbert, Matthew ;
Szaflarska, Anna ;
Sediva, Anna ;
Belohradsky, Bernd H. ;
Jones, Alison ;
Baumann, Ulrich ;
Meyts, Isabelle ;
Kutukculer, Necil ;
Wagstrom, Per ;
Galal, Nermeen Mouftah ;
Roesler, Joachim ;
Farmaki, Evangelia ;
Zinovieva, Natalia ;
Ciznar, Peter ;
Papadopoulou-Alataki, Efimia ;
Bienemann, Kirsten ;
Velbri, Sirje ;
Panahloo, Zoya ;
Grimbacher, Bodo .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (01) :116-+
[9]   Seasonal infectious disease epidemiology [J].
Grassly, Nicholas C. ;
Fraser, Christophe .
PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2006, 273 (1600) :2541-2550
[10]   Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) [J].
Herdman, M. ;
Gudex, C. ;
Lloyd, A. ;
Janssen, M. F. ;
Kind, P. ;
Parkin, D. ;
Bonsel, G. ;
Badia, X. .
QUALITY OF LIFE RESEARCH, 2011, 20 (10) :1727-1736